Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 4 , Pages 352-362 , December 2007

Human Papillomavirus and Vaccination in Cervical Cancer

  • Kung-Liahng Wang

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr Kung-Liahng Wang, Director of the Division of Gynecologic Oncology, Department of Obstetrics and Gyne-cology, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan

,Accepted 14 September 2007.

References 

  1. Bosch FX , Manos MM , Munoz N , et al.   Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group . J Natl Cancer Inst . 1995;87:796–802
  2. Parkin DM , Bray F , Ferlay J , Pisani P . Global cancer statistics, 2002 . CA Cancer J Clin . 2005;55:74–108
  3. Wang PD , Lin RS . Epidemiology of cervical cancer in Taiwan . Gynecol Oncol . 1996;62:344–352
  4. Lai MY , Chou P . Effectiveness of screening for cervical cancer in Taiwan. A case-control study . Zhonghua Yi Xue Za Zhi (Taipei) . 1992;49:81–85 [In Chinese]
  5. Bureau of Health Promotion  , Department of Health, Taiwan  . The Annual Decrease in Incidence and Mortality Rates of Cervical Cancer in Taiwan [in Chinese] . Available at: http://www.bhp.doh.gov.tw/asp/themeParkId=510/960305/pdf/951116.pdf [Date accessed: 22 March 2007]
  6. Renshaw AA, Mody DR, Lozano RL, Volk EE, Walsh MK, Davey DD, et al. Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions . Arch Pathol Lab Med . 2004;128:153–157
  7. Walboomers JM , Jacobs MV , Manos MM , et al.   Human papillomavirus is a necessary cause of invasive cervical cancer worldwide . J Pathol . 1999;189:12–19
  8. Bosch FX , Lorincz A , Munoz N , Meijer CJ , Shah KV . The causal relation between human papillomavirus and cervical cancer . J Clin Pathol . 2002;55:244–265
  9. Nobbenhuis MA , Walboomers JM , Helmerhorst TJ , et al.   Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study . Lancet . 1999;354:20–25
  10. Jacobs MV , Zielinski D , Meijer CJ , et al.   A simplified and reliable HPV testing of archival Papanicolaou-stained cervical smears: application to cervical smears from cancer patients starting with cytologically normal smears . Br J Cancer . 2000;82:1421–1426
  11. Castle PE , Wacholder S , Lorincz AT , et al.   A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women . J Natl Cancer Inst . 2002;94:1406–1414
  12. Bosch FX , de Sanjose S . Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality . J Natl Cancer Inst Monogr . 2003;3–13
  13. Cates W . Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel . Sex Transm Dis . 1999;26(4 Suppl):S2–S7
  14. Weinstock H , Berman S , Cates W . Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000 . Perspect Sex Reprod Health . 2004;36:6–10
  15. Centers for Disease Control and Prevention  . Genital HPV infection factsheet . Available at: http://www.cdc.gov/std/HPV/STDFact-HPV.htm [Date accessed: 21 March 2007]
  16. Bernard HU . Phylogeny and taxonomy of papillomaviruses . In:  Campo MS editors. Papillomavirus Research: From Natural History to Vaccines and Beyond . Norfolk, UK: Caister Academic Press; 2006;p. 11–17
  17. de Villiers EM , Fauquet C , Broker TR , Bernard HU , zur Hausen H . Classification of papillomaviruses . Virology . 2004;324:17–27
  18. Sundberg JP , Van Ranst M , Burk RD , Jenson AB . The nonhuman (animal) papillomaviruses: host range, epitope conservation, and molecular diversity . In:  Gross G ,  von Krogh G editor. Human Papillomavirus Infections in Dermato-venereology . Boca Raton: CRC Press; 1997;p. 47–68
  19. Sundberg JP , Van Ranst M , Van Ranst Montali R , et al.   Feline papil-lomas and papillomaviruses . Vet Pathol . 2000;37:1–10
  20. Tachezy R , Rector A , Havelkova M , et al.   Avian papillo-maviruses: the parrot Psittacus erithacus papillomavirus (PePV) genome has a unique organization of the early protein region and is phylogenetically related to the chaffinch papillomavirus . BMC Microbiol . 2002;2:19
  21. Orth G , Jablonska S , Breitburd F , Favre M , Croissant O . The human papillomaviruses . Bull Cancer . 1978;65:151–164
  22. Howley PM . Papillomaviridae: the viruses and their replication . In:  Fields BN ,  Knipe DM ,  Howley PM editor. Fields Virology . Philadelphia: Lippincott-Raven; 1996;p. 2045–2076
  23. Baker CC , Phelps WC , Lindgren V , Braun MJ , Gonda MA , Howley PM . Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines . J Virol . 1987;61:962–967
  24. Bryan JT , Brown DR . Transmission of human papillomavirus type 11 infection by desquamated cornified cells . Virology . 2001;281:35–42
  25. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture . J Virol . 1991;65:4860–4866
  26. von Knebel Doeberitz M , Oltersdorf T , Schwarz E , Gissmann L . Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells . Cancer Res . 1988;48:3780–3786
  27. Munger K , Howley PM . Human papillomavirus immortalization and transformation functions . Virus Res . 2002;89:213–228
  28. Davey DD . Cervical cytology classification and the Bethesda System . Cancer J . 2003;9:327–334
  29. Auvinen E , Crusius K , Steuer B , Alonso A . Human papillo-mavirus type 16 E5 protein . Int J Oncol . 1997;11:1297–1304
  30. Doorbar J . The papillomavirus life cycle . J Clin Virol . 2005;32(Suppl 1):S7–S15
  31. Gillison ML , Shah KV . Chapter 9: Role of mucosal human papillomavirus in nongenital cancers . J Natl Cancer Inst Monogr . 2003;57–65
  32. The Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group  . Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial . J Natl Cancer Inst . 2000;92:397–402
  33. Manos MM , Kinney WK , Hurley LB , et al.   Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results . JAMA . 1999;281:1605–1610
  34. Schlecht NF , Kulaga S , Robitaille J , et al.   Persistent human papillomavirus infection as a predictor of cervical intraep-ithelial neoplasia . JAMA . 2001;286:3106–3114
  35. Ho GY , Bierman R , Beardsley L , Chang CJ , Burk RD . Natural history of cervicovaginal papillomavirus infection in young women . N Engl J Med . 1998;338:423–428
  36. Moscicki AB , Hills N , Shiboski S , et al.   Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females . JAMA . 2001;285:2995–3002
  37. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer . J Infect Dis . 1999;180:1415–1423
  38. Likes WM , Itano J . Human papillomavirus and cervical cancer: not just a sexually transmitted disease . Clin J Oncol Nurs . 2003;7:271–276
  39. Bernard HU . The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses . J Clin Virol . 2005;32(Suppl 1):S1–S6
  40. Munoz N , Bosch FX , de Sanjose S , et al.   Epidemiologic classification of human papillomavirus types associated with cervical cancer . N Engl J Med . 2003;348:518–527
  41. Kreimer AR , Clifford GM , Boyle P , Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review . Cancer Epidemiol Biomarkers Prev . 2005;14:467–475
  42. Clifford GM , Smith JS , Aguado T , Franceschi S . Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis . Br J Cancer . 2003;89:101–105
  43. Clifford GM , Smith JS , Plummer M , Munoz N , Franceschi S . Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis . Br J Cancer . 2003;88:63–73
  44. Chan PK, Mak KH, Cheung JLK, Tang NL, Chan DP, Lo KK, et al. Genotype spectrum of cervical human papillo-mavirus infection among sexually transmitted disease clinic patients in Hong Kong . J Med Virol . 2002;68:273–277
  45. Bauer HM , Ting Y , Greer CE , et al.   Genital human papillo-mavirus infection in female university students as determined by a PCR-based method . JAMA . 1991;265:472–477
  46. Moscicki AB . Impact of HPV infection in adolescent populations . J Adolesc Health . 2005;37(6 Suppl):S3–S9
  47. Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, et al. Determinants of genital human papillomavirus infection in young women . J Natl Cancer Inst . 1991;83:997–1003
  48. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship . BJOG . 2002;109:96–98
  49. Palefsky JM . Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy . Curr Opin Oncol . 2003;15:382–388
  50. Koskela P , Anttila T , Bjorge T , et al.   Chlamydia trachomatis infection as a risk factor for invasive cervical cancer . Int J Cancer . 2000;85:35–39
  51. Hagensee ME , Cameron JE , Leigh JE , Clark RA . Human papil-lomavirus infection and disease in HIV-infected individuals . Am J Med Sci . 2004;328:57–63
  52. Heard I . Cervical disease and cancer in HIV positive women. Recommendations for screening and diagnosis . Med Wieku Rozwoj . 2003;7:479–485
  53. Branca M , Garbuglia AR , Benedetto A , et al.   Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up . Int J STD AIDS . 2003;14:417–425
  54. Conti M, Agarossi A, Parazzini F, Muggiasca ML, Boschini A, Negri E, et al. HPV, HIV infection, and risk of cervical intraepithelial neoplasia in former intravenous drug abusers . Gynecol Oncol . 1993;49:344–348
  55. Winer RL , Lee SK , Hughes JP , Adam DE , Kiviat NB , Koutsky LA . Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students . Am J Epidemiol . 2003;157:218–226
  56. Brown DR , Shew ML , Qadadri B , et al.   A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women . J Infect Dis . 2005;191:182–192
  57. Revzina NV , Diclemente RJ . Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review . Int J STD AIDS . 2005;16:528–537
  58. Castle PE , Schiffman M , Herrero R , et al.   A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica . J Infect Dis . 2005;191:1808–1816
  59. Kotloff KL , Wasserman SS , Russ K , et al.   Detection of genital human papillomavirus and associated cytological abnormalities among college women . Sex Transm Dis . 1998;25:243–250
  60. Damasus-Awatai G , Freeman-Wang T . Human papilloma virus and cervical screening . Curr Opin Obstet Gynecol . 2003;15:473–477
  61. Dunne EF , Markowitz LE . Genital human papillomavirus infection . Clin Infect Dis . 2006;43:624–629
  62. Molano M , Van den Brule A , Plummer M , et al.   Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study . Am J Epidemiol . 2003;158:486–494
  63. Ho GY , Burk RD , Klein S , et al.   Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia . J Natl Cancer Inst . 1995;87:1365–1371
  64. Moore MA , Tajima K . Cervical cancer in the Asian Pacific: epidemiology, screening and treatment . Asian Pac J Cancer Prev . 2004;5:349–361
  65. Baseman JG , Koutsky LA . The epidemiology of human papil-lomavirus infections . J Clin Virol . 2005;32(Suppl 1):S16–S24
  66. Trottier H , Franco EL . The epidemiology of genital human papillomavirus infection . Vaccine . 2006;24(Suppl 1):S1–S15
  67. Centers for Disease Control and Prevention  . Report to Congress: prevention of genital human papillomavirus infection . Available at: http://www.cdc.gov/std/HPV/2004HPVReport.pdf [Date accessed: 9 February 2005]
  68. Christopher A . Hearing addresses condoms for HPV prevention . J Natl Cancer Inst . 2004;96:985
  69. Frega A, Cenci M, Stentella P, Cipriano L, De Ioris A, Alderisio M, et al. Human papillomavirus in virgins and behaviour at risk . Cancer Lett . 2003;194:21–24
  70. Frasier LD . Human papillomavirus infections in children . Pediatr Ann . 1994;23:354–360
  71. Plummer M , Herrero R , Franceschi S , et al.   Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study . Cancer Causes Control . 2003;14:805–814
  72. Magnusson PK , Gyllensten UB . Cervical cancer risk: is there a genetic component? . Mol Med Today . 2000;6:145–148
  73. Magnusson PK , Sparen P , Gyllensten UB . Genetic link to cervical tumours . Nature . 1999;400:29–30
  74. Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, et al. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylo-mata acuminata . Nature . 1985;317:639–641
  75. Kreider JW , Howett MK , Leure-Dupree AE , Zaino RJ , Weber JA . Laboratory production in vivo of infectious human papillomavirus type 11 . J Virol . 1987;61:590–593
  76. Bonnez W , Rose RC , Da Rin C , Borkhuis C , de Mesy Jensen KL , Reichman RC . Propagation of human papillo-mavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model . Virology . 1993;197:455–458
  77. Meyers C , Frattini MG , Hudson JB , Laimins LA . Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation . Science . 1992;257:971–973
  78. Dillner J . The serological response to papillomaviruses . Semin Cancer Biol . 1999;9:423–430
  79. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection . J Infect Dis . 2000;181:1911–1919
  80. Carter JJ , Madeleine MM , Shera K , et al.   Human papillo-mavirus 16 and 18 L1 serology compared across anogeni-tal cancer sites . Cancer Res . 2001;61:1934–1940
  81. Sharma D . Paper smear method for rapid HPV testing . Lancet Oncol . 2002;3:454
  82. US Food and Drug Administration  . New device approval: Digene Hybrid Capture 2 High-Risk HPV DNA Test—P890064 S009 A004 . Available at: http://www.fda.gov/cdrh/mda/docs/p890064s009.html [Date accessed: 5 Aug 2007]
  83. Molijn A , Kleter B , Quint W , van Doorn LJ . Molecular diagnosis of human papillomavirus (HPV) infections . J Clin Virol . 2005;32(Suppl 1):S43–S51
  84. American Cancer Society  . Cancer Facts and Figures 2004 . Atlanta: American Cancer Society; 2004;
  85. Cox JT . Management of cervical intraepithelial neoplasia . Lancet . 1999;353:857–859
  86. Centers for Disease Control and Prevention  . Incidence of Pap test abnormalities within 3 years of a normal Pap test—United States, 1991–1998 . MMWR Morb Mortal Wkly Rep . 2000;49:1001–1003
  87. Ferlay J , Bray F , Pisani P , Parkin DM . Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide . Lyons, France: IARC Press; 2001;
  88. International Agency for Research on Cancer Working Group on evaluation of cervical cancer screening programmes  . Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies . Br Med J (Clin Res Ed) . 1996;293:659–664
  89. Sasieni PD , Cuzick J , Lynch-Farmery E . Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group . Br J Cancer . 1996;73:1001–1005
  90. Lorincz AT , Richart RM . Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs . Arch Pathol Lab Med . 2003;127:959–968
  91. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review . Ann Intern Med . 2000;132:810–819
  92. Chesson HW , Blandford JM , Gift TL , Tao G , Irwin KL . The estimated direct medical cost of sexually transmitted diseases among American youth, 2000 . Perspect Sex Reprod Health . 2004;36:11–19
  93. Saslow D , Runowicz C , Solomon D , et al. , American Cancer Society    American Cancer Society guideline for the early detection of cervical neoplasia and cancer . CA Cancer J Clin . 2002;52:342–362
  94. Morantz C , American Cancer Society  . ACS guidelines for early detection of cancer . Am Fam Physician . 2004;69:2013
  95. American College of Obstetricians and Gynecologists  . ACOG Practice Bulletin No. 66. Management of abnormal cervical cytology and histology . Obstet Gynecol . 2005;106:645–664
  96. American College of Obstetricians and Gynecologists  . ACOG Practice Bulletin No. 61. Human papillomavirus . Obstet Gynecol . 2005;105:905–918
  97. American College of Obstetricians and Gynecologists  . ACOG Practice Bulletin No. 45. Cervical cytology screening . Obstet Gynecol . 2003;102:417–427
  98. Wright TC , Cox JT , Massad LS , Twiggs LB , Wilkinson EJ . 2001 consensus guidelines for the management of women with cervical cytological abnormalities . JAMA . 2002;287:2120–2129
  99. Wright TC , Schiffman M , Solomon D , et al.   Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening . Obstet Gynecol . 2004;103:304–309
  100. Vassilakos P , Saurel J , Rondez R . Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories . Acta Cytol . 1999;43:65–68
  101. International Agency for Research on Cancer  . IARC Handbooks of Cancer Prevention Vol 10: Cervix Cancer Screening . Lyon: IARC Press; 2005;
  102. Cuzick J , Beverley E , Ho L , et al.   HPV testing in primary screening of older women . Br J Cancer . 1999;81:554–558
  103. Cuzick J , Szarewski A , Cubie H , et al.   Management of women who test positive for high-risk types of human papillomavirus: the HART study . Lancet . 2003;362:1871–1876
  104. Franco EL , Ferenczy A . Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities . Am J Obstet Gynecol . 1999;181:382–386
  105. Kuhn L , Denny L , Pollack A , Lorincz A , Richart RM , Wright TC . Human papillomavirus DNA testing for cervical cancer screening in low-resource settings . J Natl Cancer Inst . 2000;92:818–825
  106. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillo-mavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral . JAMA . 2002;288:1749–1757
  107. Macaskill P , Walter SD , Irwig L , Franco EL . Assessing the gain in diagnostic performance when combining two diagnostic tests . Stat Med . 2002;21:2527–2546
  108. Sasieni P , Cuzick J . Could HPV testing become the sole primary cervical screening test? . J Med Screen . 2002;9:49–51
  109. Solomon D , Schiffman MH , Tarone R . Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial . J Natl Cancer Inst . 2001;93:293–299
  110. Arbyn M , Buntinx F , Van Ranst M , Paraskevaidis E , Martin-Hirsch P , Dillner J . Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia . J Natl Cancer Inst . 2004;96:280–293
  111. ASCUS-LSIL Triage Study (ALTS) Group  . Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance . Am J Obstet Gynecol . 2003;188:1383–1392
  112. Clavel C , Masure M , Bory JP , et al.   Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women . Br J Cancer . 2001;84:1616–1623
  113. Sherman ME , Lorincz AT , Scott DR , et al.   Baseline cytology, human papillomavirus testing, and risk for cervical neopla-sia: a 10-year cohort analysis . J Natl Cancer Inst . 2003;95:46–52
  114. Woodman CB , Collins S , Winter H , et al.   Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study . Lancet . 2001;357:1831–1836
  115. Goldie SJ , Kim JJ , Wright TC . Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more . Am J Obstet Gynecol . 2004;103:619–631
  116. Cox JT , Schiffman M , Solomon D , ASCUS-LSIL Triage Study (ALTS) Group  . Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy . Am J Obstet Gynecol . 2003;188:1406–1412
  117. Cox JT . Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management . Obstet Gynecol Surv . 2006;61(6 Suppl 1):S15–S25
  118. Zhou J , Sun XY , Stenzel DJ , Frazer IH . Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles . Virology . 1991;185:251–257
  119. Kirnbauer R , Booy F , Cheng N , Lowy DR , Schiller JT . Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic . Proc Natl Acad Sci USA . 1992;89:12180–12212
  120. Rose RC , Bonnez W , Reichman RC , Garcea RL . Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles . J Virol . 1993;67:1936–1944
  121. White WI , Wilson SD , Bonnez W , Rose RC , Koenig S , Suzich JA . In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillo-mavirus type 16 . J Virol . 1998;72:959–964
  122. Koutsky LA , Ault KA , Wheeler CM , Brown DR , Barr E , Alvarez FB , et al.   A controlled trial of a human papillo-mavirus type 16 vaccine . N Engl J Med . 2002;347:1645–1651
  123. Villa LL , Costa RL , Petta CA , et al.   Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial . Lancet Oncol . 2005;6:271–278
  124. Advisory Committee on Immunization Practices  . ACIP provisional recommendations for the use of quadrivalent HPV vaccine . Available at: http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf [Date accessed: 30 August 2006]
  125. Sanders GD , Taira AV . Cost-effectiveness of a potential vaccine for human papillomavirus . Emerging Infect Dis . 2003;9:37–48
  126. HPV vaccine fights cervical cancer . CA Cancer J Clin . 2006;56:249–250
  127. Hughes JP , Garnett GP , Koutsky L . The theoretical population-level impact of a prophylactic human papil-loma virus vaccine . Epidemiology . 2002;13:631–639
  128. Harper DM , Franco EL , Wheeler CM , et al.   Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial . Lancet . 2006;367:1247–1255
  129. Mao C , Koutsky LA , Ault KA , et al.   Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithe-lial neoplasia: a randomized controlled trial . Obstet Gynecol . 2006;107:18–27
  130. Goldie SJ , Grima D , Kohli M , Wright TC , Weinstein M , Franco E . A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine . Int J Cancer . 2003;106:896–904
  131. Harro CD , Pang YY , Roden RB , et al.   Safety and immuno-genicity trial in adult volunteers of a human papillo-mavirus 16 L1 virus-like particle vaccine . J Natl Cancer Inst . 2001;93:284–292
  132. Schiller JT , Lowy DR . Prospects for cervical cancer prevention by human papillomavirus vaccination . Cancer Res . 2006;66:10229–10232

PII: S1028-4559(08)60004-2

doi: 10.1016/S1028-4559(08)60004-2

Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 4 , Pages 352-362 , December 2007

Article Tools